V

Vogenx

VOGXRecent IPO

Vogenx, Inc. · Nasdaq · Clinical-stage biotechnology · Report filing 2026/08/12 · SEC checked 2026-10-07

SEC
DAILY SEC UPDATE424B4 analysed from the latest filing

Vogenx is offering 6,250,000 common shares at $13.00 per share under Nasdaq symbol VOGX.

One-minute decisionBASIC RESEARCHSource completeness · 84%

Newly listed — review valuation, deal quality and post-IPO supply before acting

Vogenx, Inc. began trading on 2026-08-12 at an IPO price of $13.00; the final prospectus and offer terms are linked to SEC EDGAR.

Where does the money go?—No estimate is substituted for missing offer terms.
Ownership and votingExisting holders~55.1%* economic · Not separately disclosed voting
Next disclosed checkpointFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility

Capital destination

—

No estimate is substituted for missing offer terms.

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
Next checkFirst post-IPO filing and lock-up scheduleMonitor closing, option exercise, earnings and resale eligibility

Capital destination

—

No estimate is substituted for missing offer terms.

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
BOOKRUNNERS / LEAD UNDERWRITERSSole book-running manager
CONFIRMED
  1. 1JonesTrading Institutional Services LLC100.00%6,250,000 shares
The complete final-prospectus syndicate and each disclosed purchase commitment are shown below.Allocation basis: Final base underwriting commitment: 6,250,000 shares. Percentages are calculated from the final prospectus table and rounded to two decimals. This is underwriting commitment, not fees or post-listing ownership.Source · 424B4 ↗

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · 424B4 ↗

Existing holders

~55.1%*

The estimate compares offered shares with the latest reported shares outstanding and is not a voting-control conclusion.

Latest available filing · 2026/08/12

Review the beneficial-ownership table and voting rights together

One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

Calendar dates from 2026-08-12

  1. First trading day6.250M IPO shares
Holder / event
Holder / eventTerm / dateConditions
First trading day2026-08-12 ~44.9%* · 6.250M IPO shares6.250M IPO shares
Basis and evidence
First trading day

First trading day · 6.250M IPO shares

Lock-up / shares eligible for future sale ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

Risk 1

Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.

Potential impact
High
Monitor
First post-IPO filing and lock-up schedule
Document424B4✓ Verified against the SEC source · SEC source document
Filed2026/08/121 public filings identified
Research updated2026/08/12SEC EDGAR
Evidence coverage84%Final prospectus, offer price, listing date and headline financial evidence reconciled
Open filing ↗

What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.

View the filing's actual first page
Vogenx, Inc. 424B4 first page
424B4 first pageFirst page from SEC EDGAR